Navigation Links
ThermoGenesis Announces Axp Approval In Thailand

RANCHO CORDOVA, Calif., MAY 22, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, today said that it received regulatory approval in Thailand for its AXP® AutoXpress® Platform (AXP) used for the processing of cord blood. The Company said it expects to initiate commercial activities in the country later this year.

"We already have a strong presence in the region's cord blood market through our efforts in China, Malaysia and India, and this approval is an important step in our strategy to expand the geographic reach of our products," said Matthew Plavan, Chief Executive Officer.

"The number of cord blood banks per capita in urban areas of Thailand exceeds that of many larger countries in the region. We believe this reflects the country's appreciation for the clinical benefits of cord blood stem cells, which should translate into high demand for quality processing and storage as the country adopts automation," Plavan added.  "As a result, we consider Thailand to be an important strategic target with high potential for conversion to automated processing. This approval positions us to begin aggressively marketing the benefits of AXP automation," he noted.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
  • The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site:
Contact: Investor Relations
+1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
2. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
3. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
4. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
5. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
6. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
7. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
8. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2012 Results on November 10, 2011
10. ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent
11. ThermoGenesis Presentation at Rodman & Renshaw Conference
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer ... 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that on ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center ... with eating disorders as a result of the $20,000 raised at the center’s ... Fox Run Golf Club in Eureka, will help individuals who otherwise might not ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):